

QUIZ

8/9/2025

Dr Kishore S Dharan
Consultant Nephrologist
MOSC Medical College, Kolenchery

Question No: 1

All are true about Simplicity 3 – HTN trial in renal denervation therapy in hypertension except

1. Lack of response at 6months follow up, but significant benefits in BP control at 36 months
2. Frequent medication changes affected the out come
3. Multi electrode based sympathetic denervation
4. Sham controlled trial with largest patient numbers evaluation Renal denervation till date

ANSWER

- **Ans: 3. Multi electrode based sympathetic denervation**
- SYMPLICITY HTN-3 trial (published in 2014; randomized sham controlled) was the **largest trial**, evaluating radiofrequency renal denervation for resistant hypertension.
- Denervation method was **single electrode, targeting the main Renal artery**
- The trial **did not find a significant reduction in office systolic blood pressure** compared to the sham group at six months; but **final 36-month report showed larger blood pressure reductions**
- Potential reasons for the trial's initial failure to show efficacy,
 - Medication non-adherence in the study population
 - Technical limitations of the first-generation device
 - Inadequate ablation procedures

FIRST QUESTION WINNER

Dr.Urvashi Khan

3rd Year DrNB Nephrology
Resident.

Dharamshila Narayana Super
speciality Hospital, Delhi.



Question No: 2

The true statement about Zilbesiran, the new trial drug in antihypertensive therapy is

1. Once weekly subcutaneous administration
2. iRNA therapy directed against Aldosterone synthase
3. Reduces hepatic angiotensinogen levels significantly
4. Kardia -3 showed statistically significant double digit BP reduction

ANSWER

Ans: 3. Reduces hepatic angiotensinogen levels significantly

Zilebesiran is an RNA interference therapeutic agent with a prolonged duration of action, **inhibits hepatic angiotensinogen synthesis**

Angiotensinogen levels fell rapidly after the administration of single doses of zilebesiran and remained suppressed through week 24

In Phase II KARDIA-3 study, zilebesiran demonstrated **clinically meaningful , but statistically not significant** reductions in office systolic blood pressure at month three with continuous control through month six

Dose – Subcutaneous every 6 months

SECOND QUESTION WINNER

Dr.Urvashi Khan

3rd Year DrNB Nephrology
Resident.

Dharamshila Narayana Super
speciality Hospital, Delhi.



Thank You